Sector: Health Care
Director information for NOVAVAX INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| CHARLES W. NEWTON | Independent Director; Former Chief Financial Officer | 55 | ["Chief Financial Officer at Lyell Immunopharma, Inc. (2021 to 2025)","Managing Director & Co-Head of Healthcare Investment Banking in the Americas at Bank of America (2015 to 2021)","Managing Director, Co-Head of Healthcare Investment Banking in the Americas at Credit Suisse (2010 to 2015)","Managing Director and Head of Western Region Healthcare Investment Banking at Morgan Stanley (June 1996 to September 2010)","Experience on various public pharmaceutical company boards","M.B.A. from The Tuck School of Business at Dartmouth College","Bachelor of Science in Finance from Miami University","Industry Experience","Executive Leadership","Accounting, Financial or Investment Experience","Public Company Board"] | ["Audit","Nominating & Corporate Governance","Capital Allocation","Nominating and Corporate Governance Committee"] | 2026 |
| David Mott | Private Investor; Chairman of the Board; CHAIRMAN OF THE BOARD; Member | 60 | ["Industry Experience","Executive Leadership","Accounting, Financial or Investment Experience","Cybersecurity/IT/AI","Public Company Board","Chief Executive Officer and Chief Investment Officer at Sphinx Mountain Capital LLC","Private investor at Mott Family Capital","General Partner at New Enterprise Associates","President and Chief Executive Officer at MedImmune","Served in various senior roles including Chief Operating Officer and Chief Financial Officer","More than three decades of global management, board, and investment experience","presiding at all meetings of the Board","advising Board committee chairs","serving as a liaison between the Board and senior management team","mentoring and advising the chief executive officer","providing an extensive network of contacts","reporting regularly to the Board"] | ["Compensation","Research & Development","Capital Allocation","Research and Development Committee"] | 2026 |
| Gregg H. Alton | [] | ["Nominating and Corporate Governance Committee"] | 2026 | ||
| GREGG H. ALTON, J.D. | Independent Director; Former Interim Chief Executive Officer and Chief Patient Officer | 60 | ["Served in leadership roles at Gilead Sciences for more than 20 years","Interim Chief Executive Officer","Chief Compliance Officer","Oversight for commercial operations in multiple global regions","General Counsel and Chief Patient Officer","Attorney specializing in corporate finance transactions","Industry Experience","Executive Leadership","Accounting, Financial or Investment Experience","Cybersecurity/IT/AI","Public Company Board"] | ["Audit","Nominating and Corporate Governance","Capital Allocation"] | 2026 |
| John C Jacobs | President and Chief Executive Officer | [] | [] | 2026 | |
| John C. Jacobs | President and Chief Executive Officer and Director | 59 | ["Industry Experience","Executive Leadership","Accounting, Financial or Investment Experience","Public Company Board","Leadership experience in the biotechnology industry","Held several leadership positions for commercial biotechnology companies","general charge and supervision of the business of the Company","managing risks the Company faces in the ordinary course of operating the business","focusing the Company to execute its corporate growth strategy","positioning the Company to deliver long-term growth","President and Chief Executive Officer at Novavax, Inc.","President and Chief Executive Officer and board member at Harmony Biosciences Holdings, Inc.","Executive Vice President and Chief Commercial Officer at Harmony Biosciences Holdings, Inc.","Senior Vice President and General Manager of the Respiratory Business Unit at Teva Pharmaceuticals Industries Ltd.","Senior Vice President of Commercial Operations and Innovation at Teva","Vice President and General Manager of Teva’s Branded Business in Canada","M.B.A. from the State University of New York at Binghamton","Bachelor of Science in Business from State University of New York College at Plattsburgh"] | [] | 2026 |
| John W. Shiver | ["Industry Experience","Executive Leadership","Cybersecurity/IT/AI","Public Company Board"] | [] | 2026 | ||
| John W. Shiver, Ph.D. | Head of Research and Development; Independent Director; Member | 68 | ["Head of Research and Development at Vibrant Biomedicines (2024 to present)","Special Advisor at F-Prime Capital (2021 to present)","Adjunct Professor at University of Pennsylvania, College of Medicine (2008 to present)","Chief Strategy Officer at IGM ID, Infectious Disease Business Unit (2021 to 2023)","Senior Vice President at Sanofi Pasteur (2013 to 2020)","Vice President, Vaccine Basic Research & Franchise Head at Merck & Co., Inc. (2007 to 2013)","Vice President, Vaccines & Biologics Research at Merck & Co., Inc. (2004 to 2007)","Executive Director, Vaccines Research at Merck & Co., Inc. (1991 to 2004)","Ph.D. in Physical Chemistry, University of Florida","Bachelor of Science in Chemistry and Mathematics, Wofford College","More than 30 years of experience in pharmaceutical research and development","Experience with machine learning and artificial intelligence for vaccine development"] | ["Compensation","Research & Development","Research and Development Committee"] | 2026 |
| Margaret G. McGlynn | [] | ["Nominating and Corporate Governance Committee"] | 2026 | ||
| MARGARET G. MCGLYNN, R.Ph. | Independent Director; Former President, Merck Vaccines and Infectious Disease; Member | 66 | ["President and Chief Executive Officer at International AIDS Vaccine Initiative","Leadership roles at Merck for more than two decades","Experience in pharmaceutical and vaccine industries","Experience in for-profit and non-profit vaccine organizations","Deep experience in vaccine commercialization and understanding of global public health","Industry Experience","Executive Leadership","Scientific, Research or Development Experience","Accounting, Financial or Investment Experience","Cybersecurity/IT/AI","Public Company Board"] | ["Nominating & Corporate Governance","Research & Development","Research and Development Committee"] | 2026 |
| RACHEL K. KING | Independent Director; Founder and former Chief Executive Officer | 66 | ["Interim Chief Executive Officer at Biotechnology Innovation Organization (2022 to 2024)","Founder and former Chief Executive Officer at GlycoMimetics, Inc. (2003 to 2021)","Executive in Residence at New Enterprise Associates (2001 to 2003)","Senior Vice President at Novartis Corporation (1999 to 2001)","Chief Executive Officer of GTI, a wholly owned subsidiary of Novartis (1996 to 1998)","Vice President for Product Planning at Novartis (1993 to 1996)","Manager of Laboratory Operations at Novartis (1989 to 1993)","M.B.A. from Harvard Business School","Bachelor of Arts from Dartmouth College","Industry Experience","Executive Leadership","Scientific, Research or Development Experience","Accounting, Financial or Investment Experience","Public Company Board"] | ["Compensation","Nominating & Corporate Governance","Nominating and Corporate Governance Committee"] | 2026 |
| Richard H. Douglas, Ph.D. | Former Senior Vice President, Corporate Development; Independent Director; Member | 73 | ["Industry Experience","Executive Leadership","Accounting, Financial or Investment Experience","Public Company Board","Former Senior Vice President, Corporate Development at Genzyme Corporation","Led Genzyme Corporation’s Corporate Development team","Involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances","Served in science and corporate development capacities at Integrated Genetics","Postdoctoral fellow at the California Institute of Technology","Ph.D. in Biochemistry from University of California, Berkeley","Bachelor of Science in Chemistry from University of Michigan"] | ["Audit","Research & Development","Research and Development Committee"] | 2026 |
| Richard J. Rodgers | Former Executive Vice President, and Chief Financial Officer; Independent Director | 59 | ["Industry Experience","Executive Leadership","Scientific, Research or Development Experience","Accounting, Financial or Investment Experience","Cybersecurity/IT/AI","Public Company Board","Former Co-Founder, Executive Vice President, Chief Financial Officer, Secretary, and Treasurer at TESARO, Inc.","Chief Financial Officer and Senior Vice President of Abraxis BioScience, Inc.","Senior Vice President, Controller and Chief Accounting Officer of MGI PHARMA, Inc.","Significant business experience in the biopharmaceutical field","Financial expertise"] | ["Audit","Compensation","Capital Allocation"] | 2026 |
